SCHEMBL738706

SCHEMBL738706

O=c1cc(-c2ccccc2)oc2cc(O)c(OS(=O)(=O)O)c(O)c12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREB1 P16220 6/20 0.72
FLT3 P36888 3/20 0.72
PRSS1 P07477 2/20 0.72
PRSS2 P07478 2/20 0.72
PRSS3 P35030 2/20 0.72
SLCO2B1 O94956 2/20 0.72
PTPRS Q13332 2/20 0.69
ABCB1 P08183 6/20 0.66
MEN1 O00255 5/20 0.66
MAPT P10636 5/20 0.66
KMT2A Q03164 5/20 0.66
GABRP O00591 3/20 0.66
GABRD O14764 3/20 0.66
GABRA1 P14867 3/20 0.66
GABRB1 P18505 3/20 0.66
GABRG2 P18507 3/20 0.66
GABRB3 P28472 3/20 0.66
GABRA5 P31644 3/20 0.66
GABRA3 P34903 3/20 0.66
GABRA2 P47869 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22966701 0.90 ABCB1 (0.66) CREB1FLT3PRSS1PRSS2PRSS3
SCHEMBL739689 0.89 CREB1 (0.60) CREB1FLT3PRSS1PRSS2PRSS3
SCHEMBL738096 0.88 CREB1 (0.69) CREB1FLT3PRSS1PRSS2PRSS3
Oroxylin A SCHEMBL30452350 0.84 CREB1 (1.00) CREB1FLT3PRSS1PRSS2PRSS3
Oroxylin A SCHEMBL431423 0.84 CREB1 (1.00) CREB1FLT3PRSS1PRSS2PRSS3
Baicalein SCHEMBL28132467 0.83 ABCB1 (0.89) CREB1FLT3PRSS1PRSS2PRSS3
SCHEMBL971997 0.82 CREB1 (0.75) CREB1FLT3PRSS1PRSS2PRSS3
SCHEMBL27712859 0.82 TYR (0.76) CREB1FLT3PRSS1PRSS2PRSS3
Baicalein SCHEMBL28910096 0.82 ABCB1 (0.86) CREB1FLT3PRSS1PRSS2PRSS3
SCHEMBL972514 0.81 CREB1 (1.00) CREB1FLT3PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138165-B2 Chromones and chromone derivatives and uses thereof JENKEN BIOSCIENCES, INC. (US) 2012-03-20 US claimed
EP-1556031-A4 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES INC (US) 2009-03-25 EP claimed
US-20060142211-A1 Chromones and chromone derivatives and uses thereof TAIWANJ PHARMACEUTICALS CO., LTD. (TW) 2006-06-29 US claimed
EP-1556031-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF Jenken Bioscience, Inc. (US) 2005-07-27 EP claimed
WO-2004037193-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES, INC. (US) 2004-05-06 WO claimed
US-8138165-B2 Chromones and chromone derivatives and uses thereof JENKEN BIOSCIENCES, INC. (US) 2012-03-20 US disclosed
EP-1556031-A4 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES INC (US) 2009-03-25 EP disclosed
US-20060142211-A1 Chromones and chromone derivatives and uses thereof TAIWANJ PHARMACEUTICALS CO., LTD. (TW) 2006-06-29 US disclosed
EP-1556031-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF Jenken Bioscience, Inc. (US) 2005-07-27 EP disclosed
WO-2004037193-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES, INC. (US) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142211-A1 Chromones and chromone derivatives and uses thereof PROC, HMGB1, PYCARD CREB1 2646/4885FLT3 2228/4885PRSS1 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.